Citations

Clear

9383 citation(s) found for "Thomas, PS".

448 Clinical outcomes and safety of immune checkpoint inhibitors (ICI) in patients with solid tumors and paraneoplastic syndromes (PNS)
Zarif, Talal El , Khalid, Ahmed Bilal, Rahme, Serena, Salame, Marita , Am, Edward El, Ahmad, Bachar , Kaldas, David , LeBoeuf, Nicole R. , Malgeri, Andrea , Linnoila, Jenny, McKay, Rana R. , Dilling, Thomas J. , Adib, Elio , Najem, Elie, Sonpavde, Guru , Nassar, Amin H. , Kwak, Lucia , Farhat, Elias Bou , Am, Edward El, Ravishankar, Arjun , Nana, Frank Aboubakar , Naqash, Abdul Rafeh , Sharon, Elad , Cortellini, Alessio , Gupta, Shruti , Sparks, Jeffrey A. , Hamnvik, Ole‐Petter R. , Parikh, Kaushal , Choueiri, Toni K. , Kim, So Yeon

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A498-A498

10.1136/jitc-2023-sitc2023.0448 Get It

GLIOMA-02 HISTOPATHOLOGIC AND MOLECULAR PROFILE OF GLIOMAS: A 9-YEAR RETROSPECTIVE STUDY OF CASES DIAGNOSED IN LAGOS NIGERIA
Eckel‐Passow, Jeanette E. , Badmos, Kabir, Kitange, Gaspar J. , Anunobi, C C , Jenkins, Robert B. , Odukoya, Lateef A , Kollmeyer, Thomas M. , Ida, Cristiane M. , Lachance, Daniel Honore , Fonkem, Ekokobe , Bankole, Olufemi , Daramola, Adetola Olubunmi

Mayo Clinic

Neuro-Oncology Advances | October 31, 2023 | Volume: 5 | Issue: Supplement_4 | Pages: iv1-iv1

10.1093/noajnl/vdad121.002 Get It

Abstract BACKGROUND The diagnosis and management of patients with brain tumors currently uses WHO defined morphologic and molecular features. However, neuro-oncology practice in low resource settings relies solely on histomorphology. This study aims to reclassify glioma cases diagnosed in the Department of Anatomic and Molecular Pathology Lagos University Teaching Hospital using the WHO 2021 classification. METHODS Fifty-six cases of glioma diagnosed between 2013 to 2021 were evaluated. Morphologic diagnosis was reassessed. Five-micron sections were obtained for immunohistochemistry (IHC), and genetic testing (DNA and RNA) after manual macrodissection for tumor enrichment used 10-µm sections. IHC for IDH1-R132H, ATRX, BRAF-V600E, p53, Ki67 and H3-K27M and Oncoscan chromosomal microarray analysis were performed. NGS mutation/fusion analysis and EPIC methylation array profiling are in progress. RESULTS Of the 56 cases evaluated, median age was 22 years (range, 1-60); 71% were male. The initial morphologic diagnoses included 21 pilocytic astrocytoma, 11 glioblastoma, 9 ependymoma, 7 diffuse astrocytoma, 3 anaplastic astrocytoma, 2 high-grade gliomas, 1 oligodendroglioma, 1 diffuse midline glioma, and 1 pleomorphic xanthoastrocytoma (PXA). Histomorphologic re-evaluation revealed discordant diagnosis in 29% (16/56) of cases. Of the 56 cases, 73% (41/56) had usable DNA yield and 38% (21/56) had DNA yield of ≥750ng. Chromosomal microarray analysis was completed for 50% (28/56) cases. The revised WHO 2021 diagnosis was: 5 glioblastoma IDH-wildtype, 5 pilocytic astrocytoma, 4 glioma NEC, 3 posterior fossa ependymoma, group B, 3 PXA, 3 astrocytoma IDH-mutant, 2 pediatric low-grade gliomas, 2 supratentorial ependymoma, ZFTA fusion-positive, 1 posterior fossa ependymoma, group A. In 71% (20/28) of cases with molecular testing, diagnosis was revised using WHO 2021 criteria. CONCLUSION Most cases had usable DNA. Overall, histologic re-evaluation and molecular based on the WHO 2021 criteria refined the diagnosis in 48% (27/56) of cases.
Computed tomography calcium scoring in aortic stenosis: bicuspid versus tricuspid morphology
Ye, Zi , Clavel, Marie‐Annick , Foley, Thomas A. , Pîbarot, Philippe , Enriquez‐Sarano, Maurice , Michelena, Héctor I. , Michelena, Hector I , Pibarot, Phillippe , Enriquez-Sarano, Maurice , Clavel, Marie-Annick

Mayo Clinic

Heart | October 30, 2023 | Volume: 110 | Issue: 8 | Pages: 594-602

10.1136/heartjnl-2023-323281 | PMID 37903555 Get It

Objective CT aortic valve calcium score (AVCscore) and density (AVCdensity) thresholds have been recommended for aortic stenosis (AS) severity assessment in tricuspid aortic valve (TAV). We aimed to compare AVCscore and AVCdensity in bicuspid aortic valve (BAV) versus TAV. Methods Retrospective single-centre study of patients with echocardiographic AS-severity and CT-AVC assessments within 6 months, and left ventricular ejection fraction ≥50%, all referred for clinical AS evaluation. Severe AS was defined as aortic valve area (AVA) ≤1 cm2 or indexed AVA ≤0.6cm2/m2 plus mean gradient ≥40 mm Hg or peak velocity ≥4 m/s. AVC was assessed by Agatston method. Results Of the 1957 patients, 328 had BAV and 1629 had TAV, age 65±11 vs 80±9 years (p<0.001), men 65% vs 56% (p=0.006), respectively. BAV morphology was associated with higher AVCscore and AVCdensity independent of age, comorbidities and AS severity (p<0.001) in men only (sex and BAV interaction p<0.001). In patients with severe AS, mean AVCscore and AVCdensity were higher in BAV-men than that in TAV-men (both p<0.001), but similar in BAV-women and TAV-women (both p≥0.4). Such patterns remained the same after adjustment for clinical covariates and AS severity. Best thresholds for severe AS diagnosis in BAV-men were 2916 AU by AVCscore and 600 AU/cm2 by AVCdensity which were higher than the guideline-recommended thresholds, while thresholds in BAV-women (1036 AU and 282 AU/cm2) were similar to guideline-recommended ones. Conclusion Valve calcification in AS differs according to valve morphology and sex. BAV-men with severe AS exhibit greater AVCscore and AVCdensity than TAV-men. This presents a diagnostic challenge to the current guidelines, which needs confirmation in larger studies.
First pass effect as an independent predictor of functional outcomes in medium vessel occlusions: An analysis of an international multicenter study
Radu, Răzvan Alexandru , Costalat, Vincent , Fahed, Robert , Ghozy, Sherief , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Nguyen, Thanh N. , Heit, Jeremy J. , Regenhardt, Robert W. , Diestro, Jose Danilo Bengzon , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S., Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Kyheng, Maéva , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Mowla, Ashkan , Tjoumakaris, Stavropoula I, Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Tancredi, Illario , Yedavalli, Vivek , Chervak, Lina , Aziz, Yasmin , Stracke, Christian Paul , Hecker, Constantin , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Faizy, Tobias D. , Patel, Aman B. , Lubicz, Boris , Guenego, Adrien , Klein, Piers , Nguyen, Thanh N , Heit, Jeremy J , Sweid, Ahmad , Bellante, Flavio , Forestier, Géraud , Kühn, Anna Luisa , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Faizy, Tobias D , Liebeskind, David S. , Ghozy, Sherief , Diestro, Jose Danilo B , Regenhardt, Robert W , Alexandru Radu, Răzvan , Fahed, Robert , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Hecker, Constantin , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Mowla, Ashkan , Varela, Ricardo , Siegler, James E. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Puri, Ajit S , Sibon, Igor , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Tjoumakaris, Stavropoula , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Weyland, Charlotte S. , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

European Stroke Journal | October 27, 2023 | Volume: 9 | Issue: 1 | Pages: 114-123

10.1177/23969873231208276 | PMID 37885243 Get It

Abstract Introduction: First pass effect (FPE), achievement of complete recanalization (mTICI 2c/3) with a single pass, is a significant predictor of favorable outcomes for endovascular treatment (EVT) in large vessel occlusion stroke (LVO). However, data concerning the impact on functional outcomes and predictors of FPE in medium vessel occlusions (MeVO) are scarce. Patients and Methods: We conducted an international retrospective study on MeVO cases. Multivariable logistic modeling was used to establish independent predictors of FPE. Clinical and safety outcomes were compared between the two study groups (FPE vs non-FPE) using logistic regression models. Good outcome was defined as modified Rankin Scale 0–2 at 3 months. Results: Eight hundred thirty-six patients with a final mTICI ⩾ 2b were included in this analysis. FPE was observed in 302 patients (36.1%). In multivariable analysis, hypertension (aOR 1.55, 95% CI 1.10–2.20) and lower baseline NIHSS score (aOR 0.95, 95% CI 0.93–0.97) were independently associated with an FPE. Good outcomes were more common in the FPE versus non-FPE group (72.8% vs 52.8%), and FPE was independently associated with favorable outcome (aOR 2.20, 95% CI 1.59–3.05). 90-day mortality and intracranial hemorrhage (ICH) were significantly lower in the FPE group, 0.43 (95% CI, 0.25–0.72) and 0.55 (95% CI, 0.39–0.77), respectively. Conclusion: Over 2/3 of patients with MeVOs and FPE in our cohort had a favorable outcome at 90 days. FPE is independently associated with favorable outcomes, it may reduce the risk of any intracranial hemorrhage, and 3-month mortality.
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Gräser, Yvonne , Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Leal, Sixto M. , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , Wiederhold, Nathan P. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Ahmed, Sarah A , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Luethy, Paul , Kwon-Chung, Kyung J , Nguyen, M Hong , Pancholi, Preeti , Procop, Gary W , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Roilides, Emmanuel , Wiederhold, Nathan , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2023 | Volume: 61 | Issue: 11 | Pages: No page available

10.1128/jcm.00873-23 | PMID 37882528 Get It

ABSTRACT The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.
Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females
Cooper, Isabella D. , Kyriakidou, Yvoni , Edwards, Kurtis , Petagine, Lucy , Seyfried, Thomas N. , Duraj, Tomás , Soto-Mota, Adrián , Scarborough, Andrew, Jacome, Sandra L., Brookler, Kenneth H. , Borgognoni, Valentina, Novaes, Vanusa, Al-Faour, Rima, Elliott, Bradley , Brookler, Kenneth , Elliott, Bradley T

Mayo Clinic

International Journal of Molecular Sciences | October 26, 2023 | Volume: 24 | Issue: 21 | Pages: 15621

10.3390/ijms242115621 | PMID 37958602 Get It

Most studies on ketosis have focused on short-term effects, male athletes, or weight loss. Hereby, we studied the effects of short-term ketosis suppression in healthy women on long-standing ketosis. Ten lean (BMI 20.5 ± 1.4), metabolically healthy, pre-menopausal women (age 32.3 ± 8.9) maintaining nutritional ketosis (NK) for > 1 year (3.9 years ± 2.3) underwent three 21-day phases: nutritional ketosis (NK; P1), suppressed ketosis (SuK; P2), and returned to NK (P3). Adherence to each phase was confirmed with daily capillary D-beta-hydroxybutyrate (BHB) tests (P1 = 1.9 ± 0.7; P2 = 0.1 ± 0.1; and P3 = 1.9 ± 0.6 pmol/L). Ageing biomarkers and anthropometrics were evaluated at the end of each phase. Ketosis suppression significantly increased: insulin, 1.78-fold from 33.60 (± 8.63) to 59.80 (± 14.69) pmol/L (p = 0.0002); IGF1, 1.83-fold from 149.30 (± 32.96) to 273.40 (± 85.66) µg/L (p = 0.0045); glucose, 1.17-fold from 78.6 (± 9.5) to 92.2 (± 10.6) mg/dL (p = 0.0088); respiratory quotient (RQ), 1.09-fold 0.66 (± 0.05) to 0.72 (± 0.06; p = 0.0427); and PAI-1, 13.34 (± 6.85) to 16.69 (± 6.26) ng/mL (p = 0.0428). VEGF, EGF, and monocyte chemotactic protein also significantly increased, indicating a pro-inflammatory shift. Sustained ketosis showed no adverse health effects, and may mitigate hyperinsulinemia without impairing metabolic flexibility in metabolically healthy women.
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab
Ramsower, Colleen , Robetorye, Ryan S. , Mwangi, Raphael , Maurer, Matthew J. , Villa, Diego , McDonnell, Tim, Cohen, Jonathon B. , Clot, Guillem , Bühler, Marco M. , Kulis, Marta , Giné, Eva , Cook, James R. , Hill, Brian T. , Beiske, Klaus , Reichart, Alexander, Hartmann, Sylvia , Rimsza, Lisa M. , Ramsower, Colleen A , Maurer, Matthew , Villa, Diego , Feldman, Andrew, Cohen, Jonathon B , Martin-Subero, Jose Ignacio , Cook, James R , Hill, Brian , Raess, Philipp W , Hartmann, Sylvia , Holte, Harald , Rimsza, Lisa M , Rosenthal, Allison , McDonnell, Tim, Feldman, Andrew L. , Habermann, Thomas M. , Campo, Elı́as , Raess, Philipp W. , Holte, Harald , Scott, David W.

Mayo Clinic

British Journal of Haematology | October 26, 2023 | Volume: 204 | Issue: 1 | Pages: 160-170

10.1111/bjh.19153 | PMID 37881141 Get It

SummaryMantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high‐risk call by a simplified MCL international prognostic index (s‐MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high‐risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s‐MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk‐stratify older MCL patients in future clinical trials.
Optimizing schools of cytology: Discussions from the 2022 ASC/IAC Cytology Education Symposium, North American Strategies, and European Symbiosis
LeBlanc, Jenna B., Smith, Michele A., McNair, Sean A., Hansing, Kara L. , Bammert, Catherine E., Russell, Donna , Howell, Joshua M. , Alperstein, Susan, Lennen, Kelly, Paradis, Veronika Anic, Zuylen‐Manders, Lia van, Liikanen, Eeva , Freund, Gregory G. , Davey, Diane D. , Goulart, Robert A. , Yuil‐Valdes, Ana, Brainard, Jennifer , Hitchens, Sandra W., Donnelly, Amber , Srebotnik-Kirbis, Irena , Sturgis, Charles D. , Vielh, Philippe R.

Mayo Clinic

Cytopathology | October 25, 2023 | Volume: 35 | Issue: 1 | Pages: 2-6

10.1111/cyt.13314 | PMID 37877689 Get It

AbstractThis report highlights information and outcomes from the November 2022 ASC/IAC joint Cytology Education Symposium, an annual conference organized by the Cytology Programs Review Committee. The manuscript provides information on shared educational opportunities and practices for cytology students and other learners in anatomic pathology, discusses recruitment strategies for schools of cytology, conveys teaching resources, introduces perspectives on virtual microscopy and online learning, and transmits information about wellness of students in schools of cytology.
Dependence of peripheral T‐cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach
Le, Kang , Vollenweider, J, Staudinger, Nicholas, Stenson, Mary, Bayraktar, Lara, Wellik, Linda, McPhail, Ellen D. , Witzig, Thomas E. , Witzig, T.E. , Han, JingJing, Wellik, Linda E, McPhail, Ellen Darcy , Gupta, Mamta , Vollenweider, Jordan, Han, Jingjing , Maurer, Matthew J. , Gupta, Mamta

Mayo Clinic

Hematological Oncology | October 25, 2023 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/hon.3233 | PMID 37876297 Get It

AbstractPeripheral T‐cell lymphoma (PTCL) is a clinically heterogeneous group that represents 10%–15% of all lymphomas. Despite improved genetic and molecular understanding, treatment outcomes for PTCL have not shown significant improvement. Although Janus kinase‐2 (JAK2) plays an important role in myeloproliferative neoplasms, the critical role of JAK isoforms in mediating prosurvival signaling in PTCL cells is not well defined. Immunohistochemical analysis of PTCL tumors (n = 96) revealed high levels of constitutively active JAK3 (pJAK3) that significantly (p < 0.04) correlated with the activation state of its canonical substrate STAT3. Furthermore, constitutive activation of JAK3 and STAT3 positively correlated, at least in part, with an oncogenic tyrosine phosphatase PTPN11. Pharmacological inhibition of JAK3 but not JAK1/JAK2 significantly (p < 0.001) decreased PTCL proliferation, survival and STAT3 activation. A sharp contrast was observed in the pJAK3 positivity between ALK+ (85.7%) versus ALK‐negative (10.0%) in human PTCL tumors and PTCL cell lines. Moreover, JAK3 and ALK reciprocally interacted in PTCL cells, forming a complex to possibly regulate STAT3 signaling. Finally, combined inhibition of JAK3 (by WHI‐P154) and ALK (by crizotinib or alectinib) significantly (p < 0.01) decreased the survival of PTCL cells as compared to either agent alone by inhibiting STAT3 downstream signaling. Collectively, our findings establish that JAK3 is a therapeutic target for a subset of PTCL, and provide rationale for the clinical evaluation of JAK3 inhibitors combined with ALK‐targeted therapy in PTCL.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
Harrison, Claire , Palmer, Jeanne , Gupta, Vikas , Foltz, Lynda, Fox, María Laura , Mead, Adam J. , Perkins, Andrew C. , Leahy, Michael F. , Kawashima, Jun , Ro, Sunhee , Donahue, Rafe, Gorsh, Boris , Deheshi, Samineh, Verstovšek, Srđan , Verstovsek, Srdan , Mead, Adam J , Gupta, Vikas , Perkins, Andrew C , Mesa, Ruben A. , McLornan, Donal P. , McMullin, Mary Frances , Kiladjian, Jean‐Jacques , Platzbecker, Uwe , Ross, David M , Oh, Stephen T.

Mayo Clinic

HemaSphere | October 24, 2023 | Volume: 7 | Issue: 11 | Pages: e966

10.1097/hs9.0000000000000966 | PMID 37901848 Get It

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients’ quality of life. Fatigue is a multifactorial and burdensome MF-related symptom due to its severity, persistence, and prevalence, with anemia a contributing factor and major unmet need. Clinical trials of the Janus kinase (JAK)1/JAK2/activin A receptor type 1 inhibitor momelotinib have shown consistent anemia benefits, in addition to improvements in MF-related symptoms. The phase 3 MOMENTUM trial in symptomatic and anemic patients met its primary end point, with a greater proportion having a Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS) reduction ≥50% at week 24 with momelotinib versus danazol. To support the positive primary end point result, we conducted longitudinal, responder, and time-to-event analyses of patient-reported outcomes from MOMENTUM, as measured by the MFSAF, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Patient-Reported Outcomes Measurement Information System (PROMIS) assessments. These analyses demonstrated rapid and durable response benefits with momelotinib, with achievement of first TSS response by day 29 and continued improvement over time. Improvements favored momelotinib versus danazol for each MFSAF individual item, and greater improvements were observed for disease- and cancer-related fatigue and physical functioning at week 24, with significant results for multiple items/domains across the 3 assessments. These findings are consistent in demonstrating that momelotinib provides substantial symptom benefit.